Abstract

Hyponatraemia is defined as a serum sodium concentration of 135 mmol/L or less. It is the most common electrolyte abnormality, and can be associated with significant morbidity and mortality.1 There are numerous causes and a systematic approach to the initial investigation and management is required. Clinical assessment should start with evaluation of the patient’s degree of hydration, with the measurements of serum and urine osmolality and urinary sodium concentration being the key biochemical investigations. A recent article in this journal highlighted the challenges associated with acute symptomatic hyponatraemia; this article concentrates on the more common scenario of the patient with asymptomatic hyponatraemia.
[download-attachments container="div" style="list" dipslay_icon="1" display_count="1" display__size="0"]

References

1. Arieff AI. Hyponatraemia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 1986; 314: 1529–1535.
2. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003; 37: 1694–1702.
3. Fried LF, Palevsky PM. Hyponatremia and hypernatremia. Med Clin North Am 1997; 81: 585–609.
4. Oh MS. Pathogenesis and diagnosis of hyponatremia. Nephron 2002; 92(Suppl 1): 2–8.
5. Phillips PA, Bretherton M, Johnston CI, et al. Reduced osmotic thirst in healthy elderly men. Am J Physiol 1991; 261: R166–R171.
6. Phillips PA, Johnston CI, Gray L. Disturbed fluid and electrolyte homeostasis following dehydration in elderly people. Age Ageing 1993; 22: S26–S33.
7. Takamata A, Ito T, et al. Effect of an exercise-heat acclimation program on body fluid regulatory responses to dehydration in older men. Am J Physiol 1999; 277: R1041–R1050.
8. Kugler JP, Hustead T. Hyponatraemia andf hypernatraemia in the elderly. Am Fam Physician 2000; 61: 3623–3630.
9. Beck LH. Changes in renal function with aging. Clin Geriatr Med 1998; 14: 199–209.
10. Verbalis JG, Gullans SR. Hyponatraemia causes large sustained reduction in brain content of multiple organic solutes in rats. Brain Res 1991; 567: 274–282.
11. Gullans SR, Verbalis JG. Control of brain volume during hyperosmolar and hypoosmolar conditions. Annu Rev Med 1993; 44: 289–301.
12. Subramanian D, Ayus C. Case report: Severe symptomatic hyponatremia associated with lisinopril therapy. Am Med Sci 1992; 303: 177–179.
13. Kamoi K, Ebe T, et al. Atrial natriuretic peptide in patients with the syndrome of inappropriate antidiuretic hormone secretion and with diabetes insipidus. J Clin Endocrinol Metab 1990; 70: 1385–1390.
14. drogue’ HJ, Madias NE. Hyponatremia. N Engl J Med 2000; 342: 1581– 1589.
15. Han DS, Cho BS. Therapeutic approach to hyponatremia. Nephron 2002; 92(Suppl 1): 9–13.
16. Decaux G, Musch W, Soupart A. Hyponatremia in the intensive care: from diagnosis to treatment. Acta Clin Belg 2000; 55: 68–78.
17. 17 Decaux G, Soupart A. Treatment of symptomatic hyponatremia. Am Med Sci 2003; 326: 25–30.
18. Sterns RH, Cappucio JD, Silver Sm, et al. Neurologic sequelae after treatment of severe hyponatraemia: a multicentre perspective. J Am Soc Nephrol 1994; 4: 1522–1530.
19. Sterns RH, Cappuccio JD, Silver SM, et al. Neurologic sequelae after treatment of severe hyponatremia: multicenter perspective. Am Soc Nephrol 1994; 4: 1522–1530.
20. Sterns RH. The treatment of hyponatremia: First, do no harm. Am Med 1990; 88: 557–560.
21. Sterns RH, Riggs JE, et al. Osmotic demyelination syndrome following correction of hyponatraemia. N Engl J Med 1986; 314: 1535–1542.
22. Schwartz WB, Bennett S, et al. A syndrome of renal sodium loss and hyponatraemia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957; 23: 529–542.
23. Cherrill DA, Stote RM, Birge JR, et al. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1975; 83: 654–6.
24. Verbalis JG. Vasopressin V2 receptor antagonists. Mol Endocrinol 2002; 29: 1–9.
25. Palm C, Reimann D, Gross P. The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc Res 2001; 51: 403–408.
26. Wong LL, Verbalis JG. Vasopressin V2 receptor antagonists. Cardiovasc Res 2001; 51: 391–402.
27. Wong F, Blei AT, Blendis LM, et al. vasopressin receptor antagonist (VPA985) improves serum sodium concentration in patients with hyponatremia: multicenter, randomized, placebo-controlled trial. Hepatology 2003; 37: 182–191.